Hereditary transthyretin (hATTR) amyloidosis is a rare progressive disease that is passed from parent to child. It is caused by a mutant form of the transthyretin (TTR) protein that can damage vital ...

The road trip trope is alive and well in medical marketing, as Alnylam Pharmaceuticals recently utilized the motif to raise awareness of hereditary ATTR (hATTR) amyloidosis. Last week, the ...

Wainua (eplontersen) is a prescription injection medicine that slows down nerve damage in people with a type of amyloidosis called hereditary transthyretin-mediated amyloidosis (hATTR). The FDA ...

− Phase 3b Open-Label Study Showed Treatment with Patisiran Achieved Rapid and Sustained Reduction in Serum TTR Levels in hATTR Amyloidosis Patients with Polyneuropathy Progression Following ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the first-ever recommendations for patient- and family-centred ...

The program, called Alnylam Act ®, provides genetic testing for the diagnosis of acute hepatic porphyria, primary hyperoxaluria type 1 (PH1), and hereditary ATTR (hATTR) amyloidosis. Along with ...

Hereditary ATTR (hATTR) amyloidosis is a rare condition that affects an estimated 50,000 people worldwide. Symptoms can affect multiple parts of the body, including the nervous, cardiac and ...

Hereditary transthyretin-mediated amyloidosis (hATTR) is a type of amyloidosis, which is a group of diseases where abnormal proteins (amyloids) build up and damage areas of the body. When the amyloids ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced the submission of a Type II Variation to the ...

In 2023, IQWiG determined an added benefit of vutrisiran over patisiran on the basis of a study. Now the manufacturer cites the same study in the dossier on patisiran, but interprets it completely ...

Alnylam Pharmaceuticals ALNY presented new data from its early-stage study of nucresiran (formerly ALN-TTRsc04) for treating transthyretin (ATTR) amyloidosis at a recent medical conference in Chicago.